文献速递银屑病与炎症性皮肤病

化脓性汗腺炎患者总体共病负担与银屑病及对照组的比较

Comparative Overall Comorbidity Burden Among Patients With Hidradenitis Suppurativa.
PubMed 文献 · JAMA Dermatol · 2019-01-01

匹配分析中HS队列平均Charlson共病指数(CCI)最高(1.95),高于银屑病(1.47)和对照组(0.95)(P均<.001)。13.5%的HS患者CCI≥5,其5年死亡调整风险是CCI为0者的4.97倍。

要点

  • HS患者总体共病负担高于银屑病和对照人群。
  • 13.5%的HS患者CCI≥5,与5年死亡风险升高相关。
  • HS患者常见共病包括慢性肺病、糖尿病和轻度肝病。

核心结论

  • HS患者总体共病负担高于银屑病患者和对照组。
  • 相当比例HS患者CCI≥5,且与死亡率增加相关。

研究设计与样本

  • 横截面分析,使用2013年10月1日至2018年10月1日电子健康记录数据。

主要发现

  • 匹配前平均CCI:银屑病组2.33(SD 3.13),HS组1.80(SD 2.79),对照组1.26(SD 2.35)。
  • 匹配后平均CCI:HS组1.95(SD 2.96),银屑病组1.47(SD 2.43;P < .001),对照组0.95(SD 1.99;P < .001)。
  • 516例HS患者(13.5%)CCI≥5。
  • HS患者常见共病:慢性肺病1540例(40.3%)、无慢性并发症糖尿病927例(24.3%)、轻度肝病455例(11.9%)、有慢性并发症糖尿病365例(9.6%)。
  • HS患者CCI≥5者5年死亡调整风险是CCI为0者的4.97倍(95% CI,1.49-16.63)。

关键数值与推荐

  • 主要结局为平均Charlson共病指数(CCI)评分。
  • HS患者各性别、种族和年龄组平均CCI均最高。

临床怎么用

  • HS患者共病负担高,可能需要多学科实施常规筛查措施。
  • 对HS患者应关注慢性肺病、糖尿病和肝病等共病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The overall comorbidity burden among patients with hidradenitis suppurativa (HS) has not been systematically evaluated. OBJECTIVES: To investigate the standardized overall comorbidity burden among patients with HS and to compare it with the comorbidity burden in patients with psoriasis and a control group. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional analysis was conducted of 5306 patients with HS, 14 037 patients with psoriasis, and 1 733 810 controls identified using electronic health records data from October 1, 2013, through October 1, 2018. MAIN OUTCOME AND MEASURE: The primary outcome was the mean Charlson Comorbidity Index (CCI) score. RESULTS: Each matched cohort had 3818 patients (2789 women and 1029 men; mean [SD] age, 45.7 [15.0]). Before matching, the overall mean (SD) CCI score was highest among the psoriasis cohort (2.33 [3.13]), followed by the HS cohort (1.80 [2.79]) and control cohort (1.26 [2.35]). In matched analyses, the overall mean (SD) CCI score was highest among the HS cohort (1.95 [2.96]), followed by the psoriasis cohort (1.47 [2.43]; P < .001) and control cohort (0.95 [1.99]; P < .001) patients. A total of 516 patients with HS (13.5%) had an overall mean CCI score of 5 or greater. Mean CCI score was highest for patients with HS across all sex, race, and age groups. The most common comorbidities among patients with HS were chronic pulmonary disease (1540 [40.3%]), diabetes with chronic complications (365 [9.6%]), diabetes without chronic complications (927 [24.3%]), and mild liver disease (455 [11.9%]). Patients with HS with a CCI score of 5 or greater had 4.97 (95% CI, 1.49-16.63) times the adjusted risk of 5-year mortality compared with patients with HS with a CCI score of zero. CONCLUSIONS AND RELEVANCE: Patients with HS have a higher overall comorbidity burden compared with patients with psoriasis and a control group. A significant proportion of patients with HS have CCI scores of 5 or greater, which are associated with increased mortality. This degree of comorbidity burden may warrant multidisciplinary implementation of routine screening measures.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Reddy S, Strunk A, Garg A, et al. Comparative Overall Comorbidity Burden Among Patients With Hidradenitis Suppurativa. JAMA Dermatol. 2019. PMID: 30994865. doi:10.1001/jamadermatol.2019.0164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。